Literature DB >> 6823820

Sustained beneficial effect of nifedipine in primary pulmonary hypertension.

P J De Feyter, H J Kerkkamp, J P de Jong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6823820     DOI： 10.1016/0002-8703(83)90539-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  6 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Nitric oxide for the evaluation and treatment of pulmonary hypertension in congenital heart disease.

Authors:  J P Kovalchin; A R Mott; K L Rosen; T F Feltes
Journal:  Tex Heart Inst J       Date:  1997

Review 3.  Drug treatment of primary pulmonary hypertension.

Authors:  A A McLeod; D E Jewitt
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

4.  Verapamil in primary pulmonary hypertension.

Authors:  I Malcić; D Richter
Journal:  Br Heart J       Date:  1985-03

Review 5.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

6.  Detrimental effects of verapamil in patients with primary pulmonary hypertension.

Authors:  M Packer; N Medina; M Yushak; I Wiener
Journal:  Br Heart J       Date:  1984-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.